Herceptin trastuzumab: Interim Phase III data

Interim data from the NCI-sponsored, U.S. Phase III NSABP trial in 2,085 patients showed that Herceptin plus chemotherapy met the primary endpoint of disease-free survival and the secondary endpoint o...